- Home
- BAND vs AUTL Comparison
BAND vs AUTL Comparison
Compare BAND & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAND | AUTL |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 431.2M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BAND | AUTL |
|---|---|---|
| Price | $16.21 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.40 | $8.50 |
| AVG Volume (30 Days) | 506.0K | ★ 1.4M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | $10,120,000.00 |
| Revenue This Year | $15.34 | $669.62 |
| Revenue Next Year | $7.89 | $79.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 496.00 |
| 52 Week Low | $11.33 | $1.11 |
| 52 Week High | $18.63 | $2.70 |
Technical Indicators
Market Signals| Indicator | BAND | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 65.04 | 50.71 |
| Support Level | $15.02 | $1.27 |
| Resistance Level | $17.17 | $1.74 |
| Average True Range (ATR) | 1.08 | 0.12 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 79.38 | 27.96 |
Price Performance
Historical ComparisonAbout BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.